| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |


* From the Department of Anesthesiology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan; and the
Service dAnesthésie- Réanimation, SMUR, Hôpital Beaujon, Clichy, France.
Address correspondence to: Dr. Ju Mizuno, Assistant Professor, Department of Anesthesiology, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. Phone: +81-3-5800-8668; Fax: +81-3-5800-8938; E-mail: mizuno_ju4{at}yahoo.co.jp
| Abstract |
|---|
|
|
|---|
Clinical features: A 76-yr-old man with failed back surgery syndrome underwent epiduroscopy. Sufficient lysis could not be achieved in the epidural space above the level of L4 due to dense adhesions and scar tissue. After epidural injections of iotrolan and mepivacaine, he developed motor weakness and hypoesthesia in both legs, which lasted for three hours. He also became confused, agitated, disoriented, and developed neck stiffness and tremors involving the head and legs. Computed tomography revealed diffuse contrast enhancement within the intracranial cerebrospinal fluid (CSF) spaces, indicating an intraoperative dural tear. Marked increases in serum creatinine phosphokinase and myoglobin indicated subsequent acute rhabdomyolysis. Crystalloid infusion and semi-recumbent positioning facilitated iotrolan absorption from the CSF, and the patient recovered uneventfully.
Conclusions: Dural tear during epiduroscopy may allow access of contrast media into the CSF. Neurotoxicity secondary to iotrolan within the CSF was a likely contributing factor to the encephalopathy and subsequent rhabdomyolysis. This is an instructive example of the importance of diagnosing inadvertent dural tear during epiduroscopy under iotrolan, for avoidance of adverse events such as encephalopathy and rhabdomyolysis.
| Introduction |
|---|
|
|
|---|
| Case report |
|---|
|
|
|---|
|
|
|
| Discussion |
|---|
|
|
|---|
As a contrast medium, iotrolan is considered to be associated with a lower risk of seizures and adverse events for intrathecal use, because it does not interfere with glucose metabolism and normal metabolic pathways. 6,7 However, mild side effects such as headache, neck pain, neck stiffness, tinnitus, nausea, vomiting, dizziness, and allergic reactions may occur up to two to four days following iotrolan following myelography in as many as 2436% of procedures.69 The frequency of side effects for cervical myelography may approach 56%.8 Subarachnoid injection of iotrolan actually induced agitation and seizures in a rabbit model.10 Myelography with iotrolan has also been shown to result in symptomatic aseptic chemical meningitis.11,12 Further, hydrocephalus after myelography with iotrolan has been reported, possibly due to arachnoiditis, hypersensitivity reaction, or dural sinus thrombosis.13 Rhabdomyolysis secondary to anticonvulsant-resistant seizures following myelography with iohexol, a non-ionic contrast medium, has also been reported.14 Such adverse responses may be dose-dependent.15 As iotrolan is a dimer, and thus a larger molecule compared to iohexol, it has a longer half-life in the CSF, and a decreased rate of resorption.16 The plasma concentration following subarachnoid injection of iotrolan peaks after two to six hours.17 As there are no reported side effects of epidurally-administered iotrolan, it seems very plausible that the encephalopathic signs and rhabdomyolysis observed in this patient resulted from direct neurotoxicity of iotrolan penetrating into the central nervous system via the CSF following a dural tear during epiduroscopy. This case warns of inadvertent dural tear, resulting in known neurotoxicity of iotrolan or other contrast agents.
In this patient, we opted for conservative management with iv hydration and elevation of the head and trunk18 in an effort to minimize the cephalad migration of iotolan. While use of a lumbar intrathecal catheter has been described for the purpose of performing drainage and lavage of the intrathecal space,11,13,18 we would warrant caution for the introduction of another invasive procedure without clear indications.
There are three different ways to detect a dural tear, which include direct visualization with an epiduroscope, aspiration of CSF from the epidural space, and contrast injection under fluoroscopy. In this patient, as adhesions and scar tissue were dense and an accidental dural tear might have been difficult to observe, we failed to demonstrate4,19 a dural tear initially by any of the above methods. Further, as a moderate saline infusion was used during the procedure, it was difficult to aspirate any CSF.
Marked elevations in serum CK and Mb concentrations indicated development of rhabdomyolysis. Tremors persisted for hours in this patient, and such vigorous involuntary movement might have contributed to the development of rhabdomyolysis. Further, unusual skeletal muscle hyperactivity due to vigorous struggling against physical restraint most likely contributed to exertional rhabdomyolysis20 in this patient. A malignant neuroleptic syndrome secondary to neuroleptics21 was considered unlikely, as symptoms developed before administration of chlorpromazine and haloperidol. It has been recommended that neuroleptics e.g., phenothiazine derivatives, should be discontinued 48 hr before myelography and avoided 2448 hr after myelography with iotrolan, because they reduce the seizure threshold.22 In the case of our patient, it is difficult to ascertain how the use of these neuroleptics affected the course of the psychomotor disturbance and subsequent rhabdomyolysis.
Electroencephalographic (EEG) studies have shown that radiocontrast materials can alter seizure thresholds, in the form of non-convulsive status epilepticus, including absence status epilepticus and complex partial status epilepticus.22 The symptoms are often indistinguishable from delirium.23 The psychological disorders accompanying EEG alterations are not rare in humans after cervical myelography with iotrolan.24
In conclusion, we describe a patient who experienced an acute encephalopathy and subsequent rhabdomyolysis following an accidental dural tear associated with epiduroscopy, most probably secondary to neurotoxicity of iotrolan migrating into the CSF. This case highlights a potential and serious complication of epiduroscopy where a dural tear may be difficult to diagnose. Clearly, all precautions should be taken to avoid an intrathecal injection of iotrolan, if the dura is inadvertently injured.
| Acknowledgments |
|---|
| Footnotes |
|---|
Accepted for publication October 2, 2006. Revision accepted October 20, 2006.
| References |
|---|
|
|
|---|
2 Igarashi T, Hirabayashi Y, Seo N, Saitoh K, Fukuda H, Suzuki H. Lysis of adhesions and epidural injection of steroid/local anaesthetic during epiduroscopy potentially alleviate low back and leg pain in elderly patients with lumbar spinal stenosis. Br J Anaesth 2004; 93: 1817.
3 Gill JB, Heavner JE. Visual impairment following epidural fluid injections and epiduroscopy: a review. Pain Med 2005; 6: 36774.[Medline]
4 Anderson SR. Epiduroscopy. In: Raj PP (Ed.). Textbook of Regional Anesthesia. PA: Churchill Livingstone; 2002: 78793.
5 Yokoyama M, Hanazaki M, Fujii H, et al. Correlation between the distribution of contrast medium and the extent of blockade during epidural anesthesia. Anesthesiology 2004; 100: 150410.[Medline]
6 Wagner A, Jensen C, Saebye A, Rasmussen TB. A prospective comparison of iotrolan and iohexol in lumbar myelography. Acta Radiol 1994; 35: 1825.[Medline]
7 Hoffmann B, Becker H, Wenzel-Hora BI. Influence of the spread and period of retention of iotrolan in the subarachnoid space on the side effects rate in myelography. Neuroradiology 1987; 29: 3804.[Medline]
8 Ringel K, Klotz E, Wenzel-Hora BI. Iotrolan versus iopamidol: a controlled, multicenter, double-blind study of lumbar and direct cervical myelography. Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd 1989; 128: 1537.[Medline]
9 Bien S, Schumacher M, Berger W, Wenzel-Hora BI. Iotrolan, a non-ionic dimeric contrast medium in myelography. Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd 1989; 128: 15860.[Medline]
10 Sundgren P, Baath L, Maly P. CNS-effects from subarachnoid injections of iohexol and the non-ionic dimers iodixanol and iotrolan in the rabbit. Acta Radiol 1995; 36: 30711.[Medline]
11 Bender A, Elstner M, Paul R, Straube A. Severe symptomatic aseptic chemical meningitis following myelography: the role of procalcitonin. Neurology 2004; 63: 13113.
12 Nakakoshi T, Moriwaka F, Tashiro K, Nakane K, Miyasaka K. Aseptic meningitis complicating iotrolan myelography. AJNR Am J Neuroradiol 1991; 12: 173.[Medline]
13 Tseng SH, Tseng WS. Acute hydrocephalus after iotrolan lumbar myelography. Neuroradiology 1997; 39: 8634.[Medline]
14 Canbay O, Bal N, Akinci S, Kanbak M, Aypar U. Rhabdomyolysis after intraoperative myelography. Paediatr Anaesth 2004; 14: 50913.[Medline]
15 Simon JH, Ekholm SE, Kido DK, Utz R, Erickson J. High-dose iohexol myelography. Radiology 1987; 163: 4558.[Abstract]
16 Castel JC, Dorcier F, Caille JM. Penetration of the brain by non-ionic water soluble tri- and hexaiodinated contrast media. Experimental autoradiographic study of two contrast media: iotrol and iopamidol labelled with iodine 125. Neuroradiology 1987; 29: 20610.[Medline]
17 Skutta T, Vogelsang H, Galanski M, Hammer B, Weinmann HJ. Clinical trial of iotrol for lumbar myelography. AJNR Am J Neuroradiol 1983; 4: 3023.[Abstract]
18 van der Leede H, Jorens PG, Parizel P, Cras P. Inadvertent intrathecal use of ionic contrast agent. Eur Radiol 2002; 12(Suppl 3): S8693.
19 Gillespie G, MacKenzie P. Epiduroscopy - a review. Scott Med J 2004; 49: 7981.[Medline]
20 Russell TA. Acute renal failure related to rhabdomyolysis: pathophysiology, diagnosis, and collaborative management. Nephrol Nurs J 2005; 32: 40919.[Medline]
21 Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q 2001; 72: 32536.[Medline]
22 Fedutes BA, Ansani NT. Seizure potential of concomitant medications and radiographic contrast media agents. Ann Pharmacother 2003; 37: 150610.
23 Drislane FW. Nonconvulsive status epilepticus in patients with cancer. Clin Neurol Neurosurg 1994; 96: 3148.[Medline]
24 Fiirgaard B, Madsen HH, Svare U, Eriksen FB, Skjodt T, Zeeberg I. Intracranial iotrolan distribution following cervical myelography. Postmyelographic registration of adverse effects, psychometric assessment and electroencephalographic recording. Acta Radiol 1995; 36: 7781.[Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |